Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.

Objective: We conducted a phase II trial to evaluate the activity of oral letrozole in women with relapsed or recurrent epithelial ovarian cancer.

Methods: Twenty-seven patients were treated with letrozole at a dose of 2.5 mg once a day.